2025-11-16 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data you provided, formatted for a report.

## Eli Lilly and Co. (LLY) Analysis

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 290.94%
*   **VOO Cumulative Return:** 98.45%
*   **Absolute Outperformance:** 162.6
*   **Relative Outperformance (Percentile):** 69.5

**Analysis:** LLY has significantly outperformed the S&P 500. The absolute outperformance is substantial, and the relative outperformance percentile indicates LLY's returns are historically strong compared to the benchmark, placing it in the upper range of past performance.
### Alpha,Beta Analysis

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2015-2017  | 11.0%  | 76.1%  | -17.0%  | -0.0   | 75.6   |
| 2016-2018  | 39.0%  | 68.9%  | 24.0%   | 0.1    | 103.6  |
| 2017-2019  | 41.0%  | 68.9%  | 19.0%   | 0.4    | 117.6  |
| 2018-2020  | 34.0%  | 79.8%  | 10.0%   | 0.3    | 151.1  |
| 2019-2021  | 53.0%  | 79.8%  | 7.0%    | 0.5    | 247.2  |
| 2020-2022  | 64.0%  | 79.8%  | 65.0%   | 0.4    | 327.4  |
| 2021-2023  | 125.0% | 78.9%  | 124.0%  | 0.2    | 521.7  |
| 2022-2024  | 134.0% | 81.2%  | 113.0%  | 0.2    | 691.0  |
| 2023-2025  | 182.0% | 83.5%  | 119.0%  | 0.2    | 917.6  |

**Analysis:**

*   **CAGR:**  The Compounded Average Growth Rate has been increasing substantially in recent years, especially from 2021-2025, indicating strong growth momentum.
*   **MDD:** The Maximum Drawdown is relatively high, suggesting significant volatility and potential for price declines.
*   **Alpha:** Alpha values are generally positive, with significant increases in recent years (2020-2025). This indicates that LLY is generating returns above what would be expected based on the market (S&P 500) alone.
*   **Beta:** Beta values are relatively low, suggesting that LLY's price is less sensitive to market movements than the S&P 500.
*   **Cap(B):**  The market capitalization has seen exponential growth.

### 2. Recent Price Action

*   **Current Price:** $1025.28
*   **Previous Close:** $1021.37
*   **Change:** +0.38%
*   **5-day Moving Average:** $1004.24
*   **20-day Moving Average:** $892.35
*   **60-day Moving Average:** $810.61

**Analysis:** The current price is above all three moving averages, suggesting an uptrend. The 5-day moving average is also above the 20-day and 60-day, confirming the recent upward momentum. The small positive change from the previous close indicates continued but moderate upward pressure.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 89.65 (Overbought)
*   **PPO:** 1.46
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20-day) Relative Outperformance Change:** +18.0 (Short-term Increase)
*   **Expected Return:** 71.8% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** A reading of 0.8 suggests a medium level of risk, indicating a reasonably favorable investment environment.
*   **RSI:** The high RSI indicates that LLY is overbought and may be due for a pullback or consolidation.
*   **PPO:** The PPO being positive suggests that the short-term moving average is above the long-term moving average, which confirms the upward trend in the price.
*   **Hybrid Signal:** The "Buy" signal, based on the algorithm's cash allocation and risk assessment, strengthens the bullish outlook.
*   **Recent Relative Outperformance Change:** The recent increase in relative outperformance suggests that LLY's strong performance relative to the S&P 500 has continued to improve recently.
*   **Expected Return:** The high expected return suggests strong confidence in LLY's future performance, anticipating significant outperformance relative to the S&P 500 over the long term.

### 4. Recent News & Analyst Opinions

**Recent News:**

*   Several articles highlight positive sentiment towards LLY, including Jim Cramer calling it "a Great Company."
*   Other articles discuss valuation and growth momentum.
*   LLY is featured as a stock to watch in the Wall Street Journal.

**Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.77 (~Buy)
*   **Target Price (avg/high/low):** $1003.15 / $1500.00 / $770.00
*   **Recent Rating Changes:** No recent changes.

**Analysis:** The recent news and analyst opinions are generally positive, indicating confidence in LLY's future prospects.  The average target price is slightly below the current price, but the high target price suggests some analysts see significant upside potential.

### 5. & 6. Earnings and Financial Information

**Recent Earnings:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.30 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

**Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

Capital and Profitability:

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $23.79B   | 23.46%    |
| 2025-06-30   | $18.27B   | 30.98%    |
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |

**Analysis:**

*   **Earnings:** EPS and revenue have shown significant growth, indicating strong business performance.
*   **Revenue and Profitability:** Revenue has consistently increased over the past few quarters, with strong profit margins consistently above 80%.
*   **Capital and Profitability:** Equity has grown substantially, and ROE has been volatile but generally strong, indicating efficient use of equity to generate profits.

### 7. Summary and Conclusion

Eli Lilly and Co. (LLY) presents a compelling picture based on the data provided. The company has significantly outperformed the S&P 500, demonstrated strong growth in earnings and revenue, and maintains high profit margins. Analyst opinions are generally positive, and recent news highlights positive sentiment.

However, the RSI indicates the stock is overbought, suggesting a potential pullback in the short term. While the long-term outlook is positive, potential investors should be aware of the possibility of short-term volatility. Overall, LLY appears to be a strong company with significant growth potential, but careful consideration should be given to the current valuation and technical indicators before making an investment decision.
